Rocket Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
(technical difficulty) and welcome to Day 2 of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And this afternoon, we have Rocket Pharma here with us with Gaurav Shah, the Chief Executive Officer. Gaurav is going to make a couple of opening remarks, and we'll jump into Q&A.
Thanks, Greg, for having us here. It's a wonderful conference each time. This is a year, where I believe we're going to see a lot of progress with gene therapy in general, certainly at Rocket, but across both AAV and lenti with other companies. We're very excited Rocket specifically, is poised on becoming commercial soon in 2024. So we're in a transition period from being an R&D company into being a full-on commercial company with integrated manufacturing. So we're very excited about that. We have some key inflection points, I would say, in the next 12 months around Danon, Fanconi, LAD, PKD and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
